JAMA 331 , 16721673 (2024)
Iida, T., Yamaguchi, T., et al
In cell-based functional assays, AMG 133 shows antagonist activity against human, cynomolgus monkey and rat GIPR (Fig
Among those with insurance, 30% reported that affording their share of GLP-1 costs was somewhat difficult, and 25% reported that it was very difficult
GLP-1 therapies are showing up in ophthalmic practice whether clinicians are ready for them or not, and the evidence on their ocular effects is as mixed as the patients taking them
With its once-daily dosing and proven track record, Saxenda has been charming audiences and helping them reach their weight loss goals as well